PHAXIAM Therapeutics (PHXM) 6-K PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains

UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________

FORM 6-K

________________________

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October 2023

Commission File Number: 001-38281

________________________

PHAXIAM Therapeutics S.A.

(Translation of registrant’s name into English)

________________________

60 Avenue Rockefeller

69008 Lyon France

(Address of principal executive office)

________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 Form 20-F S             Form 40-F £

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Press Release dated October 9, 2023

On October 9, 2023, Phaxiam Therapeutics S.A. issued a press release announcing a very high spectrum of activity of its anti-S.aureus (PP1493 and PP1815) phages against clinical bacterial strains.

The full text of the press release is attached as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.

EXHIBITS

Exhibit	Description
99.1	Press Release dated October 9, 2023.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		PHAXIAM Therapeutics S.A.
Date:	October 11, 2023	By:	/s/ Eric Soyer
			Name Eric Soyer
			Title: Deputy Chief Executive Officer, Chief Financial Officer and Chief Operating Officer